ANI Pharmaceuticals, Inc. (ANIP) — 分析摘要
ANI Pharmaceuticals, Inc.(ANIP)的市值为1.84十亿美元,最近一年的营收同比增长了+43.8%。净利润率为8.9%。当前市盈率为20.0倍。
核心要点
- 营收同比变化+43.8%
- 净利润率8.9%
- 市盈率20.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,ANIP的营收增长为+43.8%,市盈率为20.0倍。
ANI Pharmaceuticals, Inc. (ANIP)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
970
总部
PRINCETON, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。